ProteoStasis secures $45M in first round
Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.
The funds will support research and development for therapies to treat genetic, degenerative and metabolic disorders associated with protein homeostasis deficiencies. The startup's researchers are hoping that breakthroughs in understanding the onset of abnormal protein production will lead to more effective treatments for ailments such as Parkinson's disease, cystic fibrosis, diabetes, Alzheimer's and Huntington's.
- see the ProteoStasis release
Related Articles:
In VC market, life sciences dominate
Top 20 VC deals of 2007
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
